Improving Symptom Self-management in Adolescents & Young Adults With Cancer

Virginia Commonwealth University30 enrolled

Overview

This study evaluates the use of the Computerized Symptom Capture Tool (C-SCAT), which creates an image of the symptoms the participant is experiencing, for improving symptom self-management in adolescents and young adults with cancer. In this one-group trial, participants will complete the C-SCAT and use it during two clinic visits with their oncology providers.

Unrelieved symptoms lead to poorer quality of life for adolescents and young adults (AYAs) with cancer. Strategies are needed to help AYAs manage symptoms. The investigators developed the Computerized Symptom Capture Tool (C-SCAT), a novel way to assess symptoms where AYAs create a picture of their symptoms using images and text on an iPad app. The resulting image shows symptoms/symptom clusters, priority symptoms and relationships between symptoms and has potential to support AYA's symptom self-management. Facilitating the self-management process, including self-efficacy, self-regulation behaviors, and patient-provider communication, is essential for improving symptom outcomes.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Symptom Clusters Cancer

Interventions

Computer Symptom Capture ToolDEVICE

C-SCAT is an investigator developed app that is delivered via an iPad. The original CSCAT included the 30 symptoms from the Memorial Symptom Assessment Scale. The recently updated version includes two additional symptoms "feeling bloated" and "sexual dysfunction" that are included in the adult version of the MSAS.21 These symptoms were added based on feedback from the initial AYA sample of 13-29 year olds and in consideration of the developmental perspectives of the AYA population.The CSCAT allows the user to create an image of his or her symptom experience.

Eligibility

Sex: ALLMin age: 15 YearsMax age: 29 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 15 to 29 years of age with a diagnosis of cancer (primary, relapsed/recurrent, refractory, progressive, or secondary malignancy) receiving myelosuppressive chemotherapy. * Completion of at least one cycle of therapy for cancer and anticipated to have at least two additional cycles of myelosuppressive chemotherapy as part of the treatment plan. * Ability to speak and understand English as required to complete the C-SCAT and study measures. * Ability to use a tablet computer. Exclusion Criteria: * Cognitive and/or physical inabilities to complete the proposed study measures as determined by self--report, parent report of minor, or medical chart.

Locations (2)

The Childrens Mercy Hospital

Kansas City, Missouri, United States

Virginia Commonwealth University/Massey Cancer Center

Richmond, Virginia, United States

Outcomes

Primary Outcomes

Change in self-efficacy of symptom management measured by PROMIS Self-efficacy of symptom management scale.

Time frame: Baseline, immediately after first provider visit (approx. 2 -4 weeks from baseline) and then immediately after second provider visit (approx. 6-8 weeks from baseline)

Change in patient-provider communication from patient perspective measured by Patient-Provider Communication Scale.

Time frame: Baseline, immediately after first provider visit (approx. 2 -4 weeks from baseline) and then immediately after second provider visit (approx. 6-8 weeks from baseline)

Change in self-regulation of symptoms assessed by an audio-taped semi-structured interview.

Semi-structured interviews to address how using the C-SCAT impacts self-regulation behaviors, such as self-monitoring, reflective thinking, and decision-making

Time frame: Within 24 hours after first provider visit (approx. 2 -4 weeks from baseline) and Within 24 hours after second provider visit (approx. 6-8 weeks from baseline)

Change in provider's usefulness of using C-SCAT assessed by Provider Questionnaire.

Time frame: After first provider visit (approx. 2 -4 weeks from baseline) and after second provider visit (approx. 6-8 weeks from baseline)

Change in provider's usefulness of using C-SCAT assessed by providers' documentation of symptoms in the electronic health record.

Time frame: After first provider visit (approx. 2 -4 weeks from baseline) and after second provider visit (approx. 6-8 weeks from baseline)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.